Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Save Now, Travel through March: T'way Air Announces Fall Savings to Korea
Promo Code FLYOCT & Special Coupons for Travel through March 2026 TAIPEI, Oct. 20, 2025 /PRNewswire/ -- T'way Air, Korea's leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for...
China's enduring commitment to peaceful development: a consistent path across past, present, and future
BEIJING, Oct. 20, 2025 /PRNewswire/ -- A report from People's Daily: Amid a turbulent and rapidly evolving global landscape, one principle remains consistent in China's international engagement: its unwavering commitment to peaceful development....
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial...
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants...
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group
SYDNEY, Oct. 20, 2025 /PRNewswire/ -- The Brattle Group has welcomed Dr. Luke Wainscoat to its growing Sydney office as a Principal in the firm's Antitrust & Competition practice. An economist with 20 years of experience, Dr. Wainscoat advises...
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the...